Yüklüyor......
Novel UL97 drug resistance mutations identified at baseline in a clinical trial of maribavir for resistant or refractory cytomegalovirus infection
In a Phase 2 clinical trial, 120 subjects with cytomegalovirus (CMV) infection refractory or resistant to standard therapy were randomized equally to 3 doses of oral maribavir treatment, and 70% achieved undetectable plasma CMV DNA within 12 weeks. At study entry, standard diagnostic UL97 genotyping...
Kaydedildi:
| Yayımlandı: | Antiviral Res |
|---|---|
| Asıl Yazarlar: | , , , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
2019
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6892599/ https://ncbi.nlm.nih.gov/pubmed/31568799 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.antiviral.2019.104616 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|